Guilherme Silva, MD
Interventional Cardiology · Houston, TXNPI 1952579153
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (33.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Medtronic at 59.6% of the total. Reporting peaked in 2019 at $22,910 and has fallen 93.0% since, to $1,604 in 2025.
Across 549 payments — averaging $99.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$33K
- Abiomed$10K
- Edwards Lifesciences$4K
- Boston Scientific$3K
- Abbott$2K
- Cardiovascular Systems Inc.$641
- plus $2K from 19 others
Across 143 payments — averaging $3225.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$210K
- Abbott$179K
- Medtronic$40K
- W. L. Gore & Associates, Inc.$33K
What the payments were for
- Consulting fees$4771%
- Speaking & faculty fees$18,40634%
- Grants$550%
- Travel & lodging$18,44134%
- Food & beverage$17,33932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 210 | $32,597 |
| Abiomed | 19 | $9,897 |
| Edwards Lifesciences | 184 | $4,231 |
| Boston Scientific | 29 | $2,721 |
| Abbott | 38 | $2,421 |
| Cardiovascular Systems Inc. | 5 | $641 |
| Heartflow, Inc. | 5 | $368 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $358 |
| Ancora Heart, Inc. | 5 | $215 |
| Impulse Dynamics (USA) Inc. | 2 | $177 |
| Irhythm Technologies, Inc. | 11 | $153 |
| E.r. Squibb & Sons, L.L.C. | 2 | $135 |
| W. L. Gore & Associates, Inc. | 3 | $130 |
| Lexicon Pharmaceuticals, Inc. | 5 | $116 |
| Saranas, Inc. | 1 | $113 |
| Cardiva Medical, Inc. | 2 | $96 |
| Novartis | 4 | $79 |
| Jenavalve Technology, Inc. | 1 | $77 |
| Scpharmaceuticals Inc. | 4 | $63 |
| Novo Nordisk | 2 | $34 |
| AstraZeneca | 2 | $32 |
| Pfizer | 1 | $18 |
| Amgen | 1 | $16 |
| Baxter Healthcare | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$15,378
- CoreValve Evolut$10,586
- Impella$9,847
- GENERAL - THERAPIES$1,012
- Edwards SAPIEN 3 Transcatheter Heart Valve$911
- Diamondback Coronary$641
- ROTAWIRE$400
- Mitra Clip system$378
- OPTIMIZER$299
- AMPLATZER Occluders$282
- ROTABLATOR$249
- Diamondback Peripheral$231
- CardioMEMS HF System$168
- FFRct$148
- NAVITOR$146
- Xience Sierra Coronary Stent System$139
- XIENCE SKYPOINT$135
- MitraClip$134
- Avalus$125
- SYNERGY$125
How this compares
$54,718 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 103 | $109,398 |
| EliquisApixaban | 76 | $71,208 |
| BrilintaTicagrelor | 64 | $58,544 |
| XareltoRivaroxaban | 12 | $17,252 |
| Ranolazine ErRanolazine | 49 | $4,987 |
| Prasugrel Hcl | 14 | $2,467 |
| Metoprolol Succinate | 129 | $2,117 |
| Amiodarone Hcl | 32 | $1,715 |
| Enoxaparin Sodium | 27 | $1,572 |
| Atorvastatin Calcium | 84 | $1,013 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 89 | $1,002 |
| ClopidogrelClopidogrel Bisulfate | 93 | $750 |
| Carvedilol | 59 | $584 |
| Amlodipine Besylate | 28 | $354 |
| Rosuvastatin Calcium | 18 | $336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $79 | $109,398103 claims |
| PfizerEliquis | $18 | $71,20876 claims |
| AstraZenecaBrilinta | $32 | $58,54464 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Juan GranadaHouston$4.1M
- John IsaacHouston$1.8M
- Sanjay KunapuliHouston$267K
- Michele SartoriHouston$266K
- Abhijeet DhobleHouston$161K
- Amir KashaniHouston$148K
- Dhaval ParekhHouston$137K
- Neal KleimanHouston$118K
- Mehran MassumiHouston$114K
- Eduardo HernandezHouston$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.